Cargando…

Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice

Rheumatoid arthritis (RA) is an autoimmune disease associated with the recognition of self proteins secluded in diarthrodial joints. We have previously established that mice transgenic for the human DR genes associated with RA are susceptible to collagen-induced arthritis (CIA) and we have identifie...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakurai, Yoshihiko, Brand, David D, Tang, Bo, Rosloniec, Edward F, Stuart, John M, Kang, Andrew H, Myers, Linda K
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779432/
https://www.ncbi.nlm.nih.gov/pubmed/16982003
http://dx.doi.org/10.1186/ar2043
_version_ 1782131770007748608
author Sakurai, Yoshihiko
Brand, David D
Tang, Bo
Rosloniec, Edward F
Stuart, John M
Kang, Andrew H
Myers, Linda K
author_facet Sakurai, Yoshihiko
Brand, David D
Tang, Bo
Rosloniec, Edward F
Stuart, John M
Kang, Andrew H
Myers, Linda K
author_sort Sakurai, Yoshihiko
collection PubMed
description Rheumatoid arthritis (RA) is an autoimmune disease associated with the recognition of self proteins secluded in diarthrodial joints. We have previously established that mice transgenic for the human DR genes associated with RA are susceptible to collagen-induced arthritis (CIA) and we have identified a determinant of type II collagen (CII(263–270)) that triggers T-cell immune responses in these mice. We have also determined that an analog of CII(263–270 )would suppress disease in DR1 transgenic mice. Because the immunodominant determinant is the same for both DR1 transgenic and DR4 transgenic mice, we attempted to determine whether the analog peptide that was suppressive in DR1 transgenic mice would also be effective in suppressing CIA in DR4 transgenic mice. We treated DR4 transgenic mice with two analog peptides of CII that contained substitutions in the core of the immunodominant determinant: CII(256–276 )(F263N, E266D) and CII(256–270 )(F263N, E266A). Mice were observed for CIA, and T-cell proliferative responses were determined. Either peptide administered at the time of immunization with CII significantly downregulated arthritis. Binding studies demonstrated that replacement of the phenylalanine residue in position 263 of the CII peptide with asparagine significantly decreased the affinity of the peptide for the DR4 molecule. In contrast, replacement of the glutamic acid residue in position 266 with aspartic acid or with alanine had differing results. Aspartic acid reduced the affinity (35-fold) whereas alanine did not. Both peptides were capable of suppressing CIA. With the use of either peptide, CII(256–276 )(F263N, E266D) or CII(256–270 )(F263N, E266A), the modulation of CIA was associated with an increase in T-cell secretion of IL-4 together with a decrease in IFN-γ. We have identified two analog peptides that are potent suppressors of CIA in DR4 transgenic mice. These experiments represent the first description of an analog peptide of CII recognized by T cells in the context of HLA-DR4 that can suppress autoimmune arthritis.
format Text
id pubmed-1779432
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-17794322007-01-19 Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice Sakurai, Yoshihiko Brand, David D Tang, Bo Rosloniec, Edward F Stuart, John M Kang, Andrew H Myers, Linda K Arthritis Res Ther Research Article Rheumatoid arthritis (RA) is an autoimmune disease associated with the recognition of self proteins secluded in diarthrodial joints. We have previously established that mice transgenic for the human DR genes associated with RA are susceptible to collagen-induced arthritis (CIA) and we have identified a determinant of type II collagen (CII(263–270)) that triggers T-cell immune responses in these mice. We have also determined that an analog of CII(263–270 )would suppress disease in DR1 transgenic mice. Because the immunodominant determinant is the same for both DR1 transgenic and DR4 transgenic mice, we attempted to determine whether the analog peptide that was suppressive in DR1 transgenic mice would also be effective in suppressing CIA in DR4 transgenic mice. We treated DR4 transgenic mice with two analog peptides of CII that contained substitutions in the core of the immunodominant determinant: CII(256–276 )(F263N, E266D) and CII(256–270 )(F263N, E266A). Mice were observed for CIA, and T-cell proliferative responses were determined. Either peptide administered at the time of immunization with CII significantly downregulated arthritis. Binding studies demonstrated that replacement of the phenylalanine residue in position 263 of the CII peptide with asparagine significantly decreased the affinity of the peptide for the DR4 molecule. In contrast, replacement of the glutamic acid residue in position 266 with aspartic acid or with alanine had differing results. Aspartic acid reduced the affinity (35-fold) whereas alanine did not. Both peptides were capable of suppressing CIA. With the use of either peptide, CII(256–276 )(F263N, E266D) or CII(256–270 )(F263N, E266A), the modulation of CIA was associated with an increase in T-cell secretion of IL-4 together with a decrease in IFN-γ. We have identified two analog peptides that are potent suppressors of CIA in DR4 transgenic mice. These experiments represent the first description of an analog peptide of CII recognized by T cells in the context of HLA-DR4 that can suppress autoimmune arthritis. BioMed Central 2006 2006-09-18 /pmc/articles/PMC1779432/ /pubmed/16982003 http://dx.doi.org/10.1186/ar2043 Text en Copyright © 2006 Sakurai et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sakurai, Yoshihiko
Brand, David D
Tang, Bo
Rosloniec, Edward F
Stuart, John M
Kang, Andrew H
Myers, Linda K
Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice
title Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice
title_full Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice
title_fullStr Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice
title_full_unstemmed Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice
title_short Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice
title_sort analog peptides of type ii collagen can suppress arthritis in hla-dr4 (drb1*0401) transgenic mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779432/
https://www.ncbi.nlm.nih.gov/pubmed/16982003
http://dx.doi.org/10.1186/ar2043
work_keys_str_mv AT sakuraiyoshihiko analogpeptidesoftypeiicollagencansuppressarthritisinhladr4drb10401transgenicmice
AT branddavidd analogpeptidesoftypeiicollagencansuppressarthritisinhladr4drb10401transgenicmice
AT tangbo analogpeptidesoftypeiicollagencansuppressarthritisinhladr4drb10401transgenicmice
AT rosloniecedwardf analogpeptidesoftypeiicollagencansuppressarthritisinhladr4drb10401transgenicmice
AT stuartjohnm analogpeptidesoftypeiicollagencansuppressarthritisinhladr4drb10401transgenicmice
AT kangandrewh analogpeptidesoftypeiicollagencansuppressarthritisinhladr4drb10401transgenicmice
AT myerslindak analogpeptidesoftypeiicollagencansuppressarthritisinhladr4drb10401transgenicmice